{"groups":[{"description":"Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"FG000","title":"Cohort A (Alisertib, Rituximab)"},{"description":"Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"FG001","title":"Cohort B (Alisertib, Rituximab)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}